Epilepsy Market to Expand at a Significant Growth Rate During the Forecast Period (2019-32) Estimates DelveInsight | UCB, Xenon Pharma, Epygenix, Neurona, Cevevel, PTC Therapeutics, Addex Pharma, Equilibre, Anavex, Eliem, LifeSplice, Virpax, Neuroene

As per DelveInsight, the Epilepsy Market is anticipated to evolve immensely in the coming years owing to the increase in the diagnosed prevalent population of Epilepsy and the launch of new therapies in the market. Expected Launch of potential therapies like Libervant/ Diazepam Buccal Soluble Film (Aquestive Therapeutics), Staccato Alprazolam (UCB Biopharma), Soticlestat (Takeda), and others may increase the market size and the treatment outlook.

DelveInsight's "Epilepsy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Epilepsy Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Epilepsy therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Epilepsy treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Epilepsy: An Overview
According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsies are a spectrum of brain disorders ranging from severe, life-threatening, and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness.

Epilepsy also includes several syndromes based on the seizure type, which majorly include West syndrome, Lennox-Gastaut syndrome (LGS), CDKL5 Deficiency Disorder (CDD), drug-resistant epilepsy, Dravet syndrome (DS), Landau-Kleffner syndrome, epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS), protocadherin 19 (PCDH19)-related epilepsy, childhood absence epilepsy, Dup15q syndrome, photosensitive epilepsy, and others.

As there are many different types of epilepsy, there are many different causes too, which include: brain injury or damage to the brain, structural abnormalities that arise during brain development, genetic factors, infectious diseases like meningitis, AIDS, and others, and prenatal injury.

The signs and symptoms of seizures include temporary confusion, staring spells, uncontrollable jerking movements of the arms and legs, loss of consciousness or awareness, and psychic symptoms. Epilepsy treatment involves antiepileptic medications (AEDs) like sodium channel inhibitors, calcium channel inhibitors, GABA A receptor agonists, and others, diet therapy, and surgery.

Epilepsy Market Key Facts
• According to the Centers for Disease Control and Prevention (CDC) (2017) also highlights that in 2015, 1.2% of the US population had active epilepsy, which suggests that about 3.4 million people suffer from epilepsy nationwide: 3 million adults and 470,000 children. The organization also suggests that the prevalence of epilepsy is higher in adults aged over 18 years as compared to the ones aged 17 years or below.
• The Joint Epilepsy Council (2019) believes that the figure of approximately 600,000 people in the UK with diagnosed epilepsy who are receiving AED treatment is the best and most accurate estimate currently available.
• The total prevalent population of Epilepsy in the 7 major markets was found to be around 7 million in 2022.
• The total diagnosed prevalent cases of Epilepsy in 2022 was around 5 million in the 7MM, out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which was around 3 million in 2022.
• Among EU4 and the UK, the United Kingdom had the highest total prevalent population of Epilepsy, with around 600,000 cases in 2022. While, the least number of cases were in France, with approximately 400,000 cases in 2022.
• The total prevalent cases of Epilepsy in Japan was approximately 2 million in 2022.

Discover How the Epilepsy Market Will Grow by 2032:
https://www.delveinsight.com/report-store/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Epilepsy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Epilepsy therapies in the market. It also provides a detailed assessment of the Epilepsy market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Epilepsy drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Epilepsy Epidemiology
The epidemiology section covers detailed insights into the historical, and current Epilepsy patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Epilepsy Epidemiology Segmented as -
• Total Prevalent Population of Epilepsy
• Gender-specific Diagnosed Prevalent Population of Epilepsy
• Diagnosed Prevalent Population of Epilepsy Based on Seizure Types in Adults
• Total Diagnosed Prevalent Population of Epilepsy
• Diagnosed Prevalent Population of Epilepsy Based on Seizure Types in Children

Get Key Insights Into the Evolving Epilepsy Epidemiology Trends @
https://www.delveinsight.com/report-store/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Epilepsy Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to be launched during the study period. The analysis covers the market share by Epilepsy drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Epilepsy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Epilepsy Therapeutics Assessment
Treatment for epilepsy includes antiepileptic medications (AEDs), diet therapy, and surgery. Anticonvulsant therapy in adults is usually considered after two unprovoked epileptic seizures. Since most patients can be treated successfully with one agent, there is a broad consensus that therapy should be started by choosing a single antiepileptic drug of the first choice. AEDs as monotherapies or combination therapies are currently the first-line treatment. The various classes of AEDs include sodium channel inhibitors, calcium channel inhibitors, GABA A receptor agonists, synaptic vesicle protein SV2A modulators, Na/Ca channel modulators and AMPA receptor blockade.

The medications treat the symptoms of epilepsy (the seizures), rather than curing the underlying condition. They are highly effective and completely control seizures in the majority (approximately 70%) of patients. The choice of the first agent is determined by seizure type, tolerability, efficacy, and patient characteristics like age, gender, contraception, or family planning issues. There are several approved therapies in the 7MM, however, some of the recently FDA-approved epileptic drugs have been described below.

Several major pharma and biotech companies are developing therapies for Epilepsy. Currently, SK Life Science is leading the therapeutics market with its Epilepsy drug candidates in the most advanced stage of clinical development.

Leading Companies in the Epilepsy Therapeutics Market Include
• UCB
• SK Life Science
• Stoke Therapeutics
• Xenon Pharmaceuticals
• Epygenix
• Bright Minds Biosciences
• Neurona Therapeutics
• Cevevel Therapeutics
• PTC Therapeutics
• Addex Pharmaceuticals
• Equilibre Biopharmaceuticals B.V.
• ES Therapeutics Australia Pty Ltd
• Overseas Pharmaceuticals
• Anavex Life Sciences
• Eliem Therapeutics
• Ovid Therapeutics
• CAMP4 Therapeutics
• LifeSplice
• Virpax Pharmaceuticals
• Neuroene Therapeutics
And Many Others

Emerging and Marketed Epilepsy Therapies Covered in the Report Include
• ZX008 (Fenfluramine Hydrochloride): UCB
• Cenobamate: SK Life Science, Inc.
• STK-001: Stoke Therapeutics
• EPX-100: Epygenix
• NRTX-1001: Neurona Therapeutics
• BMB-101: Bright Minds Biosciences
• ENX-101: Engrail Therapeutics
• Darigabat: Cerevel Therapeutics
• XEN496:Xenon Pharmaceuticals Inc.
• AMZ002: Amzell
And Many More

Learn More About the Emerging Therapies & Key Companies in the Epilepsy Therapeutics Market:
https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Epilepsy Competitive Intelligence Analysis
4. Epilepsy Market Overview at a Glance
5. Epilepsy Background and Overview
6. Epilepsy Patient Journey
7. Epilepsy Epidemiology and Patient Population
8. Epilepsy Treatment Algorithm, Current Treatment, and Medical Practices
9. Epilepsy Unmet Needs
10. Key Endpoints of Epilepsy Treatment
11. Epilepsy Marketed Products
12. Epilepsy Emerging Therapies
13. Epilepsy Seven Major Market Analysis
14. Attribute Analysis
15. Epilepsy Market Outlook (7 major markets)
16. Epilepsy Access and Reimbursement Overview
17. KOL Views on the Epilepsy Market.
18. Epilepsy Market Drivers
19. Epilepsy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/epilepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

------------------------------------------------------------------------------------------------------------------------------
Discover DelveInsight's Comprehensive Market Research and Consulting Services:
https://www.delveinsight.com/market-research

Elevate your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at:
https://www.delveinsight.com/medical-devices

Empowering Cancer Care: DelveInsight's oncology consulting services offer personalized guidance and cutting-edge expertise to navigate the ongoing clinical, commercial, and regulatory developments, visit for more details:
https://www.delveinsight.com/oncology

Other Trending Healthcare Reports by DelveInsight
Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Varicose Ulcer Market
https://www.delveinsight.com/report-store/varicose-ulcer-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Poly (ADP-Ribose) Polymerase 1 (PARP) Inhibitor Pipeline Insight
https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Eczema Market
https://www.delveinsight.com/report-store/eczema-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Hemostats Market
https://www.delveinsight.com/report-store/hemostats-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Peripheral Vascular Devices Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Urinary Incontinence Market
https://www.delveinsight.com/report-store/urinary-incontinence-market

Hemostasis Market
https://www.delveinsight.com/report-store/hemostasis-market

Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market

Emphysema Market
https://www.delveinsight.com/report-store/emphysema-market

Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market

Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Diabetes Market
https://www.delveinsight.com/report-store/diabetes-market

Panuveitis Market
https://www.delveinsight.com/report-store/panuveitis-market

Global Kinase Inhibitor in Autoimmune Diseases Market
https://www.delveinsight.com/report-store/global-kinase-inhibitor-in-autoimmune-diseases-market

mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market

Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market

Hematuria Market
https://www.delveinsight.com/report-store/hematuria-market

Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market

Audiology Devices Market
https://www.delveinsight.com/report-store/audiology-devices-market

Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market

Prosthetic Heart Valve Market
https://www.delveinsight.com/report-store/prosthetic-heart-valve-market

Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market

Cancer Vaccines Market
https://www.delveinsight.com/report-store/cancer-vaccines-market

CAR-T Pipeline Insight
https://www.delveinsight.com/report-store/car-t-pipeline-insight

Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market

Physiotherapy Equipment Market
https://www.delveinsight.com/report-store/physiotherapy-equipment-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

Seborrhoeic Dermatitis Market
https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market

Migraine Market
https://www.delveinsight.com/report-store/migraine-market

Pegfilgrastim Biosimilar
https://www.delveinsight.com/report-store/pegfilgrastim-biosimilar-insight

Renal Vasculitis Market
https://www.delveinsight.com/report-store/renal-vasculitis-market

Dense Deposit Disease Market
https://www.delveinsight.com/report-store/dense-deposit-disease-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.